A randomized controlled study of SC-3460 in the treatment of COVID-19

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2022
INTERVENTION: experimental group:SC‐3460;control group:blank; CONDITION: Novel Coronavirus Pneumonia (COVID‐19) PRIMARY OUTCOME: Percentage of negative nucleic acid tests (Nasopharyngeal swabs/respiratory secretions); SECONDARY OUTCOME: Clinical prognosis; INCLUSION CRITERIA: 1. At least 18 years of age; 2. Within 5 days prior to screening, sarS‐COV‐2 infection was confirmed by PCR test with or without COVID‐19 related symptoms; 3. Male or female (contraceptive or infertile).
Epistemonikos ID: 587ee45ff95a3c1f51121f00e66e95c1504bb805
First added on: Apr 25, 2022